VIR BIOTECHNOLOGY

Vir is leveraging immunologic breakthroughs to address unmet patient needs in infectious disease and beyond... Vir has built a broad pipeline with several ongoing trials - including two late-stage programs in chronic hepatitis delta and chronic hepatitis B - that we believe will support near- and long-term growth, along with multiple potential INDs in the next 12-24 months... At Vir Biotechnology, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe' section below.

Also known as: Vir, Vir Biotechnology International GmbH, Vir Biotechnology, Inc TM, Vir Biotechnology, Inc.

Primary location: San Francisco United States